The argument for the importance of patient diagnosis often relies upon the efficacy of subsequent treatment. But according to a recent study, three-quarters of people would want to know if they have a particular neurological disorder even if it had no cure.
Harvard researchers have developed an inexpensive handheld device for use in the world's poorest regions that can monitor diabetes, detect malaria and analyze drinking water through electrochemical analysis and then send the information to a computer anywhere on the globe by standard mobile phone.
Abbott Laboratories and the United States Department of Defense are collaborating to develop a test that can be used to assess potential concussions quickly in the field. Abbott's handheld diagnostic i-Stat System is already in use by the military; the test will be developed for use on it.
Foundation Medicine is teaming up with the MD Anderson Cancer Center in Texas for a new trial of the the Cambridge, MA-based company's molecular diagnostic cancer test that targets therapies matched to individual patients.
Researchers have developed a device that could determine how soon patients should be fed following surgery. Patients with the intestinal problem postoperative ileus fall sick if they eat too soon after surgery and must stay in the hospital for an additional two to three days.
The FDA described the contents of its proposed regulatory framework to Congress, but the details of its plan remain a mystery. Following the July 31 notification to Congress, the agency must wait at least 60 days before the release of its draft guidance on the topic.
While test strips and expensive polymerase chain reaction (PCR) machines exist in the Ebola detection market, scientists are after a medical device that can detect and prevent the spread of Ebola at a low cost.
The National Institutes of Health (NIH) has awarded $14.5 million in eight grants to researchers working to develop high quality and low cost DNA sequencing. The grants are each for two to four years and are awarded through the Advanced DNA Sequencing Technology program of the National Human Genome Research Institute, a part of NIH.
FDA announced July 31 that it intends to issue a draft guidance soon that would require moderate and high-risk diagnostics to obtain 510(k) or PMA approval, regardless of their place of origin, putting an end to a battle to regulate laboratory-developed tests that's been waged for several years.
Researchers are hoping to get into the clinic in the next three to 5 years with a self-assembling nanoparticle that targets tumors. The idea behind the technology is to make cancer cells more identifiable when using magnetic resonance imaging screening.